2002, setting a one-month term for reply. As this response is being submitted before the end of the term for reply, it is believed that no fees are necessary, however, the Commissioner is authorized to charge any fee, or credit any overpayment, to Deposit Account 50-0320.

Applicants respectfully request acceptance of the enclosed paper copy and computer readable form of the Sequence Listing.

AMENDMENT

It is respectfully requested that the application be amended, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as follows:

IN THE SPECIFICATION:

Page 8, line 11, please rewrite the paragraph thereat as follows:

In one embodiment of the present invention the target cell is of a type which may be lysed as a result of an immunological response thereagainst. Advantageously, the target cell is a tumour cell or any diseased or foreign cell the presence of which is undesired in a patient, such as a cancer cell, leukaemia cell, a cell infected with the HIV virus or with any other microbe or virus, a cell responsible for detrimental activity in auto-immune disease, and so on. In order to accelerate the triggering of an immunological response against said target cell in a patient, said HLA class I molecule or fragment thereof will preferably be capable of producing a powerful immune response from the cellular immune system of the patient. Accordingly, said HLA class I molecule or fragment thereof may bind a viral or microbial peptide, preferably a viral or microbial peptide to which the patient is likely to have had previous exposure. In particular, said HLA class I molecule or fragment thereof may bind an influenza virus peptide, a measles virus peptide, an Epstein-Barr virus peptide, in particular an Epstein-Barr virus peptide comprising the RAKFFQLL (SEQ ID NO: 1) epitope of the lytic protein BZLFI, a Cytomegalovirus peptide, or a tetanus toxoid peptide. Alternatively, said HLA class I molecule or fragment thereof may bind any peptide which already has a strong cytotoxic T cell response or which is capable of inducing a powerful immune response. The allotype of said HLA class I molecule or fragment thereof may additionally be different from the allotype of the HLA class I molecules of the patient, so that an alloreactive response may additionally be triggered against said target cell.

Page 24, line 3, please rewrite the paragraph thereat as follows:

T cells : Human cytotoxic T cell clones 010 (specific for HLA-A2/gag 77-85 = SLYNTVATL (SEQ ID NO: 2) (Parker et al, J Immunol. 149. 1992, 3580-3587)) and IF9 (specific for HLA-A2/melan-A 26-35 = EAAGIGILTV (SEQ ID NO: 3) (Romero et al, J. Immunol. 159, 1997, 2366) were maintained in media supplemented with 5% human serum and IL-2 100 IU/ml.

Immediately after page 28 and before the first page of claims (page 29), please insert the enclosed pages identified as --Sequence Listing--.